Table 6.
Univariate and multivariate Cox proportional hazard model recurrence free survival analysis for clinicopathologic features and adaptive T cell and macrophage phenotypes in CLM with preoperative chemotherapy (n-56).
| Factor | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (year) | 0.99 | 0.961–1.018 | 0.458 | |||
| Gender | 0.93 | 0.524–1.665 | 0.817 | |||
| Primary tumor location | 0.94 | 0.474–1.859 | 0.855 | |||
| Primary tumor T stage (T3-T4) | 2.07 | 0.497–8.577 | 0.318 | |||
| Primary nodal status (N1) | 1.33 | 0.687–2.585 | 0.396 | |||
| Synchronous liver metastasis | 1.25 | 0.671–2.318 | 0.485 | |||
| Preoperative CEA level (>5 ng/mL) | 0.81 | 0.444–1.466 | 0.482 | |||
| Post hepatectomy chemotherapy | 1.90 | 0.874–4.123 | 0.106 | |||
| Diameter of largest liver metastasis (>5 cm) | 0.56 | 0.236–1.332 | 0.190 | |||
| Number of liver metastasis | 1.38 | 0.765–2.475 | 0.286 | |||
| Liver resection margin | 0.96 | 0.379–2.448 | 0.936 | |||
| Major pathological responsea | 1.45 | 0.792–2.657 | 0.229 | |||
| Cell phenotype | ||||||
| CD68+ | 0.63 | 0.345–1.142 | 0.127 | |||
| CD68+pSMAD3+ | 2.01 | 1.113–3.634 | 0.021 | 1.96 | 1.052–3.655 | 0.034 |
| CD68+TGFb+ | 0.88 | 0.490–1.594 | 0.681 | |||
| CD68+FOXP+ | 0.91 | 0.487–1.709 | 0.776 | |||
| CD68+CD163+ (M2) | 0.44 | 0.235–0.833 | 0.012 | 0.69 | 0.262–1.815 | 0.450 |
| CD68+CD86+ (M1) | 1.67 | 0.895–3.119 | 0.107 | |||
Factors with a threshold p value < 0.10 were selected for the final model.
HR hazard ratio, CI confidence interval, CEA carcinoembryonic antigen, CLM colorectal liver metastasis.
aData of major pathological response was missing in 3 patients.
Statistically significant p-values are in bold